SCHEMBL647516

SCHEMBL647516

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(F)c(Br)c1)CC1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HDAC1 Q13547 1/20 0.35
TSHR P16473 5/20 0.33
KDM4E B2RXH2 4/20 0.33
ALDH1A1 P00352 4/20 0.33
CRHR1 P34998 3/20 0.33
CYP3A4 P08684 3/20 0.33
HSD17B10 Q99714 3/20 0.33
HPGD P15428 2/20 0.33
CCR4 P51679 1/20 0.32
BCHE P06276 3/20 0.32
ALOX15 P16050 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
ADORA2A P29274 1/20 0.31
ADORA2B P29275 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135166 0.93 C5AR1 (0.45) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL650928 0.90 C5AR1 (0.43) C5AR1CYP2D6HDAC1TSHRKDM4E
SCHEMBL5135213 0.90 C5AR1 (0.42) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL5137096 0.89 C5AR1 (0.42) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL651431 0.89 C5AR1 (0.43) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL649094 0.89 C5AR1 (0.43) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL5137114 0.88 C5AR1 (0.43) C5AR1CYP2D6HDAC1TSHRKDM4E
SCHEMBL5135753 0.88 C5AR1 (0.43) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL651006 0.88 C5AR1 (0.42) C5AR1HDAC1TSHRKDM4EALDH1A1
SCHEMBL650474 0.88 C5AR1 (0.42) C5AR1CYP2D6HDAC1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed